Supplementary Methods, Figures 1, 3-7, Tables 1 - 4, 8 from Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids

Table S1: Peaks used for the calibration of mass spectral data sets related to the Materials and Methods section. Table S2: Peaks used for the calibration of mass spectral data sets related to the Materials and Methods section. Table S3: Peaks used for the calibration of mass spectral data sets related to the Materials and Methods section. Table S4: Peaks used for the calibration of mass spectral data sets related to the Materials and Methods section. Figure S1: Schematic showing the method for the MSMS-stitch technique related to the Materials and Methods section. Table S8: Mass spectrometry 13C-glucose tracer lipidomics phosphatidylcholine data related to the "BaP treatment decreases fatty acid and phospholipid synthesis and increases triacylglycerol levels" results section. Figure S3A: The absolute mass spectral intensities of 13C labelled phosphatidylcholine (PC) species in HL60 cells after BaP treatment in the presence of 1-13C D-glucose. This is related to the "BaP treatment decreases fatty acid and phospholipid synthesis and increases triacylglycerol levels" results section. Figure S3B: The absolute mass spectral intensities of 12C phosphatidylcholine (PC) species in HL60 cells after BaP treatment in the presence of 1-13C D-glucose. This is related to the "BaP treatment decreases fatty acid and phospholipid synthesis and increases triacylglycerol levels" results section. Figure S4: Heatmaps showing the fold changes of individual phosphatidylcholine (PC) species in HL60 cells after BaP treatment in the presence of 1-13C D-glucose. This is related to the "BaP treatment decreases fatty acid and phospholipid synthesis and increases triacylglycerol levels" results section. ( Figure S5A: The absolute mass spectral intensities of 13C labelled free fatty acids in HL60 cells after BaP treatment in the presence of 13C D-glucose. This is related to the "A commercial SCD1 inhibitor can partially recapitulate the effect of BaP on lipogenesis" section. Figure S5B: The absolute mass spectral intensities of 13C labelled saturated (SFA: C16:0 and C18:0) and monounsaturated (MUFA: C16:1 and C18:1) free fatty acids in HL60 cells after BaP treatment in the presence of 13C D-glucose. This is related to the "A commercial SCD1 inhibitor can partially recapitulate the effect of BaP on lipogenesis" section. Figure S6A: The absolute mass spectral intensities of 13C labelled phosphatidylcholine (PC) in HL60 cells after BaP treatment in the presence of 13C D-glucose. This is related to the "A commercial SCD1 inhibitor can partially recapitulate the effect of BaP on lipogenesis" section. Figure S6B: The absolute mass spectral intensities of 12C labelled phosphatidylcholine (PC) in HL60 cells after BaP treatment in the presence of 13C D-glucose. This is related to the "A commercial SCD1 inhibitor can partially recapitulate the effect of BaP on lipogenesis" section. Figure S7: Images of cells supplemented with oleic acid related to the "Oleate decreases the levels of BaP-induced reactive oxygen species (ROS)" results section. "